礼来BTK抑制剂匹妥布替尼在中国获批上市
MPA
发表于 2024-10-30 13:07:42
193
0
0
据介绍,匹妥布替尼是礼来研发的first-in-class(首创新药)非共价BTK C481S抑制剂。该产品分别于2023年1月和2023年12月获得美国FDA加速批准,分别用于既往接受过至少二线系统治疗(包括BTK抑制剂)的复发或难治性MCL成人患者,以及既往接受过至少二线系统治疗(包括BTK抑制剂和BCL-2抑制剂)的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤(CLL/SLL)成人患者。
公开资料显示,匹妥布替尼是获FDA批准的首个非共价(可逆转)BTK抑制剂,也是首个获批用于治疗已对BTK共价抑制剂产生抗性的MCL患者的BTK抑制剂。
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.